We are live on ! Find out more
1CM

1492 Capital Management Portfolio holdings

AUM $263M
1-Year Est. Return 61.9%
This Fund
S&P 500
This Quarter Est. Return
+2.27%
1 Year Est. Return
+61.9%
3 Year Est. Return
+187.15%
5 Year Est. Return
+242.53%
10 Year Est. Return
+2,731.07%
AUM
$107M
AUM Growth
-$11.2M
Cap. Flow
-$8.41M
Cap. Flow %
-7.87%
Top 10 Hldgs %
38.95%
Holding
106
New
22
Increased
11
Reduced
40
Closed
24

Sector Composition

Rank Sector Weight
1 Technology 25.41%
2 Healthcare 22.18%
3 Consumer Discretionary 12.42%
4 Communication Services 10.75%
5 Energy 7.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SAIL
101
DELISTED
SailPoint Technologies Holdings, Inc. Common Stock
SAIL
-23,207
Closed -$667K
CLDR
102
DELISTED
Cloudera, Inc.
CLDR
-92,248
Closed -$1.01M
HOME
103
DELISTED
At Home Group Inc.
HOME
-40,728
Closed -$727K
FSB
104
DELISTED
Franklin Financial Network, Inc.
FSB
-30,946
Closed -$898K
LTXB
105
DELISTED
LegacyTexas Financial Group Inc
LTXB
-9,789
Closed -$366K
HZNP
106
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
-193,063
Closed -$5.1M

Similar funds

1492 Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, 1492 Capital Management held 106 positions worth $107M, down 9.5% from $118M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

1492 Capital Management withdrew a net $8.41M in Q2 2019, closing 24 positions and reducing 40 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $5.1M position sold in full.

By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 24% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, 1492 Capital Management opened a new position in Pilgrim's Pride worth $1.81M.

  • 1492 Capital Management's largest Q2 2019 buy was Pilgrim's Pride: 71,417 shares worth $1.81M.
  • 1492 Capital Management added most to Vonage Holdings Corporation in Q2 2019, an estimated $2.11M increase.
  • 1492 Capital Management's biggest Q2 2019 reduction was NeoGenomics, cutting an estimated $2.58M.
  • 1492 Capital Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2019, selling an estimated $5.1M.
  • 1492 Capital Management's ten largest holdings make up 39% of its $107M portfolio in Q2 2019.
  • 1492 Capital Management opened 22 new positions and closed 24 in Q2 2019.
  • 1492 Capital Management's portfolio value fell 9.5% quarter-over-quarter to $107M.

Based on 1492 Capital Management's 13F filing for Q2 2019, filed 6 Aug 2019.